EDP Sciences logo
Submit your paper
Search
Menu
Home All issues Volume 22 / No 2 (avril 2016) Med Buccale Chir Buccale, 22 2 (2016) 137-143 References
Open Access
Issue
Med Buccale Chir Buccale
Volume 22, Number 2, avril 2016
Page(s) 137 - 143
Section Cas clinique et revue de la littérature / Up-to date review and case report
DOI https://doi.org/10.1051/mbcb/2016018
Published online 30 May 2016
  1. Bascones-Martínez A, García-García V, Meurman JH, Requena-Caballero L. Immune-mediated diseases: what can be found in the oral cavity? Int J Dermatol 2015;54:258-270. [CrossRef] [PubMed] [Google Scholar]
  2. Arisawa EA, Almeida JD, Carvalho YR, Cabral LA. Clinicopathological analysis of oral mucous autoimmune disease: A 27-year study. Med Oral Patol Oral Cir Bucal 2008;13:E94-97. [PubMed] [Google Scholar]
  3. Roujeau J-C. Érythème polymorphe. EMC - Dermatol 2008;3:1-9. [CrossRef] [Google Scholar]
  4. Vargas-Hitos JA, Manzano-Gamero MV, Jiménez-Alonso J. Erythema multiforme associated with Mycoplasma pneumoniae. Infection 2014;42:797-798. [CrossRef] [PubMed] [Google Scholar]
  5. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-96. [CrossRef] [PubMed] [Google Scholar]
  6. HAS. Thalidomide - Erythème polymorphe - thalidomide_erytheme_polymorphe.pdf. L.162-17-2-1 août, 2008. [Google Scholar]
  7. Hirsch G, Ingen-Housz-Oro S, Fite C, Valeyrie-Allanore L, Ortonne N, Buffard V, et al. Rituximab, a new treatment for difficult-to-treat chronic erythema multiforme major? Five cases. J Eur Acad Dermatol Venereol 2015;15. [Google Scholar]
  8. Margolis RJ, Tonnesen MG, Harrist TJ, Bhan AK, Wintroub BU, Mihm MC, et al. Lymphocyte subsets and Langerhans cells/indeterminate cells in erythema multiforme. J Invest Dermatol 1983;81:403-406. [CrossRef] [PubMed] [Google Scholar]
  9. Kokuba H, Aurelian L, Burnett J. Herpes simplex virus associated erythema multiforme (HAEM) is mechanistically distinct from drug-induced erythema multiforme: interferon-gamma is expressed in HAEM lesions and tumor necrosis factor-alpha in drug-induced erythema multiforme lesions. J Invest Dermatol 1999;113:808-815. [CrossRef] [PubMed] [Google Scholar]
  10. Larcher C, Gasser A, Hattmannstorfer R, Obexer P, Fürhapter C, Fritsch P, et al. Interaction of HSV-1 infected peripheral blood mononuclear cells with cultured dermal microvascular endothelial cells: a potential model for the pathogenesis of HSV-1 induced erythema multiforme. J Invest Dermatol 2001;116:150-156. [CrossRef] [PubMed] [Google Scholar]
  11. Ono F, Sharma BK, Smith CC, Burnett JW, Aurelian L. CD34+ cells in the peripheral blood transport herpes simplex virus DNA fragments to the skin of patients with erythema multiforme (HAEM). J Invest Dermatol 2005;124:1215-1224. [CrossRef] [PubMed] [Google Scholar]
  12. Gober MD, Laing JM, Burnett JW, Aurelian L. The Herpes simplex virus gene Pol expressed in herpes-associated erythema multiforme lesions upregulates/activates SP1 and inflammatory cytokines. Dermatology 2007;215:97-106. [CrossRef] [PubMed] [Google Scholar]
  13. Akkurt ZM, Uçmak D, Türkcü G, Yüksel H, Yildiz K, Arıca M. Expression of interleukin-17 in lesions of erythema multiforme may indicate a role for T helper 17 cells. Cent-Eur J Immunol 2014;39:370-376. [CrossRef] [Google Scholar]
  14. Sugita K, Nishio D, Kabashima K, Honda M, Tokura Y. Erythema multiforme associated with Gardnerella vaginosis and elevated circulating CXCR3+ B cells. Clin Exp Dermatol 2008;33:351-353. [CrossRef] [PubMed] [Google Scholar]
  15. Vaillant L, Chauchaix-Barthès S, Hüttenberger B, Arbeille B, Machet M, Jan V, et al. [Chronic desquamative gingivitis syndrome: retrospective analysis of 33 cases]. Ann Dermatol Venereol 2000;127:381-387. [PubMed] [Google Scholar]
  16. Jimson S, Balachader N, Anita N, Babu R. Immunologically mediated oral diseases. J Pharm Bioallied Sci 2015;7 (Suppl 1):S209-S212. [CrossRef] [PubMed] [Google Scholar]
  17. CEDEF : Collège des Enseignants en Dermatologie de France. Dermatoses bulleuses auto-immunes. Ann Dermatol Vénéréologie 2008;135S:F95-F102. [Google Scholar]
  18. Zeroual N, Ledant T, Cayphas J, Boudry P, Simonart L, Mollet J-J, et al. Évaluation de quatre kit Elisa IgM; IgA et IgG dans le diagnostic sérologique d’infections à Mycoplasma pneumoniae. Immuno-Anal Biol Spéc 2007;22:401-403. [Google Scholar]
  19. Engeser P, Klimm HD. [Therapy of recurrent exudative erythema multiforme. Effectiveness of thalidomide--report of a case]. Fortschr Med 1999;117:39-40. [Google Scholar]
  20. Conejo-Mir JS, del Canto S, Muñoz MA, Rodríguez-Freire L, Serrano A, Hernandez C, et al. Thalidomide as elective treatment in persistent erythema multiforme; report of two cases. J Drugs Dermatol 2003;2:40-44. [PubMed] [Google Scholar]
  21. Chen C-W, Tsai T-F, Chen Y-F, Hung C-M. Persistent erythema multiforme treated with thalidomide. Am J Clin Dermatol 2008;9:123-127. [CrossRef] [PubMed] [Google Scholar]
  22. Cherouati K, Claudy A, Souteyrand P, Cambazard F, Vaillant L, Moulin G, et al. [Treatment by thalidomide of chronic multiforme erythema: its recurrent and continuous variants. A retrospective study of 26 patients]. Ann Dermatol Venereol 1996;123:375-377. [Google Scholar]
  23. Haute Autorité de Santé. Avis de la HAS pour la prise en charge à titre dérogatoire de certaines spécialités pharmaceutiques, produits ou prestations prévue à l’article L. 162-17-2-1 - Mabthera 500 mg (Rituximab) par voie injectable dans le traitement du pemphigus cicatriciel. 2010. [Google Scholar]
  24. Barnadas M, Roe E, Brunet S, Garcia P, Bergua P, Pimentel L, et al. Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature. J Eur Acad Dermatol Venereol 2006;20:69-74. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.